
    
      This is a Phase I, first time in human, randomised, double-blind, placebo-controlled, and
      dose escalation study.

      The study will comprise of:

        1. A Screening Period of up to 27 days (Day -28 through Day -2);

        2. A Treatment Period during which participants will be resident at the Clinical Unit from
           Day -1, 1 day before Investigational Medicinal Product (IMP) administration (on Day 1)
           until at least 24 hours after IMP administration, will be discharged on Day 2 after all
           safety evaluations have been completed, and

        3. A Follow up Period lasting 360 days (through to Day 361) after the IMP dose.

      The study will be conducted at a single study centre in United Kingdom.
    
  